These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 31128009

  • 1. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F, Cheng X, Zeng H, Miao J, Hou M.
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [Abstract] [Full Text] [Related]

  • 2. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.
    J Clin Oncol; 2017 Apr 01; 35(10):1070-1077. PubMed ID: 28113019
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Med Oncol; 2016 Aug 01; 33(8):97. PubMed ID: 27447711
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
    Zhao B, Wang Y, Wang Y, Chen W, Zhou L, Liu PH, Kong Z, Dai C, Wang Y, Ma W.
    Aging (Albany NY); 2020 Jul 15; 12(14):14244-14270. PubMed ID: 32669477
    [Abstract] [Full Text] [Related]

  • 5. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL.
    Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):673-9. PubMed ID: 27034176
    [Abstract] [Full Text] [Related]

  • 6. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.
    Radiother Oncol; 2017 May 01; 123(2):195-202. PubMed ID: 28363487
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X, Li W, Li J, Jia W, Jing W, Tian Y, Xu S, Li Y, Zhu H, Yu J.
    Radiat Oncol; 2021 Dec 05; 16(1):233. PubMed ID: 34865626
    [Abstract] [Full Text] [Related]

  • 8. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.
    J Neurooncol; 2014 Nov 05; 120(2):423-30. PubMed ID: 25098700
    [Abstract] [Full Text] [Related]

  • 9. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G, Zhang X, Tian C, Xia G, Liu P, Zhang Q, Li X, Zhang H, Qin N, Wang J, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2016 Aug 20; 19(8):501-7. PubMed ID: 27561798
    [Abstract] [Full Text] [Related]

  • 10. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
    Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC.
    Oncologist; 2019 Dec 20; 24(12):e1417-e1425. PubMed ID: 31127020
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K, Jiang G, Zhang A, Li Z, Jia J.
    BMC Cancer; 2020 Jan 30; 20(1):76. PubMed ID: 32000711
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG.
    J Clin Oncol; 2024 Oct 20; 42(30):3606-3617. PubMed ID: 39047224
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y, Wei J, Cai J, Liu A.
    BMC Cancer; 2019 Aug 09; 19(1):793. PubMed ID: 31399067
    [Abstract] [Full Text] [Related]

  • 15. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T, Zhang Y, Li X, Zhao C, Chen X, Su C, Ren S, Yang N, Zhou C.
    Eur J Cancer; 2019 Nov 09; 121():98-108. PubMed ID: 31569068
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, Zhang J.
    J Thorac Oncol; 2016 Oct 09; 11(10):1718-28. PubMed ID: 27237825
    [Abstract] [Full Text] [Related]

  • 18. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
    Yan W, Liu Y, Li J, Han A, Kong L, Yu J, Zhu H.
    Radiat Oncol; 2019 Sep 14; 14(1):168. PubMed ID: 31521171
    [Abstract] [Full Text] [Related]

  • 19. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T.
    Int J Radiat Oncol Biol Phys; 2019 Jul 01; 104(3):604-613. PubMed ID: 30851347
    [Abstract] [Full Text] [Related]

  • 20. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC.
    PLoS One; 2020 Jul 01; 15(4):e0231546. PubMed ID: 32298306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.